Lilly gets sought-after FDA designation for Alzheimer's candidate
The US FDA is accompanying the recent approval of Biogen's Alzheimer's treatment with a breakthrough therapy designation for another potential treatment of the disease.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
Eli Lilly's drug candidate donanemab treating Alzheimer's disease has received breakthrough therapy status at the US Food and Drug Administration, according to a press release from Eli Lilly.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
